Singulex, Inc.

Sara Jane Le

John Allan Todd

Richard A Livingston

Philippe J Goix

Robert Puskas

Douglas Held

Quynh Anh Thuc Lu

Quynh Anh Thue Lu

Disclosed are methods for diagnosing, staging, and predicting risk for developing rheumatoid arthritis and other inflammatory diseases, and methods for identifying treatment responders and non-responders.

Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis

Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNF&#x3b1;, IL-17) biomarkers provided a sensitivity of 94% for association with CHF.

Highly sensitive biomarker panels

Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNF&#x3b1;, IL-17a) biomarkers provided a sensitivity of 94% for association with CHF.

Growing community of inventors

Berkeley, CA, United States of America

Sara Jane Le